Home › Cardiomyopathy › NCT06610019
Cardiovascular Multimodality Imaging Study
Risk Stratification of Ischemic and Non-ischemic Cardiomyopathies in Racial and Ethnic Minority Groups in the Bronx - Cardiovascular Multimodality Imaging Study
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Any adult patient (18 years or older) referred for a cardiovascular magnetic resonance (CMR) imaging study in the Montefiore Health System Exclusion Criteria: * Any patient who does not meet above criteria
About the study
Determining the etiology of cardiomyopathy is of high clinical importance for optimal treatment strategy and prediction of prognosis. There is increased risk for cardiovascular disease and higher propensity for cardiovascular related mortality among Black and non-Hispanic White patients. Recently, advanced cardiac imaging has become a vital tool in diagnosis and risk stratification of cardiovascular disease. Very limited data is available on the prevalence and characteristics of different cardiovascular diseases in Hispanic and African American minority groups, therefore, studying different racial and ethnic minority groups in the Bronx population is an exceptionally valuable source to determine the prevalence of cardiomyopathies among minority groups along with study survival in this population. This study aims to determine the etiology of cardiovascular disease in a diverse patient population by utilizing various cardiovascular imaging modalities, with a focus on cardiac magnetic resonance (CMR) imaging and to develop risk stratification models by applying advanced cardiovascular imaging markers.
Sponsor: Montefiore Medical Center · Participants: 10,000 · Started: May 1, 2023
Contact the study team
- Annalisa Filtz, MD · Phone: 929-232-9798
Official record on ClinicalTrials.gov — NCT06610019
Locations in the U.S.
| New York | Montefiore Health System, The Bronx |
Conditions
- Cardiomyopathy
- Hypertrophic Cardiomyopathy
- Arrhythmogenic Right Ventricular Dysplasia
- Familial Amyloid Neuropathies
- Fabry Disease
- Sarcoidosis
- Heart Failure
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.